Organon & Co. (historical, later spun off)
E468962
Organon & Co. (historical, later spun off) was Merck & Co.’s women’s health and biosimilars-focused business unit that was separated into an independent pharmaceutical company.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| Organon & Co. | 1 |
Statements (30)
| Predicate | Object |
|---|---|
| instanceOf |
business unit
ⓘ
pharmaceutical business unit ⓘ |
| businessType |
biosimilars-focused business unit
ⓘ
women’s health-focused business unit ⓘ |
| corporateAction | separation of women’s health and biosimilars portfolio from Merck & Co. ⓘ |
| corporateRelationship | was internal business segment prior to spin-off ⓘ |
| countryOfParentCompany | United States NERFINISHED ⓘ |
| focusArea |
biosimilars
ⓘ
women’s health ⓘ |
| industry | pharmaceuticals ⓘ |
| parentCompany | Merck & Co., Inc. NERFINISHED ⓘ |
| parentCompanyAlsoKnownAs | Merck Sharp & Dohme (MSD) outside the United States and Canada NERFINISHED ⓘ |
| parentCompanyTicker | MRK NERFINISHED ⓘ |
| partOf | Merck & Co., Inc. NERFINISHED ⓘ |
| predecessorOf | Organon & Co. (independent company) NERFINISHED ⓘ |
| productType |
biosimilar medicines
ⓘ
pharmaceutical products ⓘ |
| reasonForSpinOff | to create a standalone company focused on women’s health and biosimilars ⓘ |
| roleWithinParent | specialized operating unit ⓘ |
| separationType | corporate spin-off ⓘ |
| spunOffInto | Organon & Co. (independent company) NERFINISHED ⓘ |
| statusAfterSpinOff | no longer a business unit of Merck & Co.; operations transferred to independent Organon & Co. ⓘ |
| successorCompanyFocus |
biosimilars
ⓘ
women’s health ⓘ |
| successorCompanyIndustry | global pharmaceutical company ⓘ |
| successorCompanyName | Organon & Co. NERFINISHED ⓘ |
| therapeuticArea |
contraception
ⓘ
fertility ⓘ menopause management ⓘ reproductive health ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
Organon & Co.